Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
capecitabine + oxaliplatin + trastuzumab
- Development stage
- Unknown
- Lead developer
- Roche
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
This is a three-drug oncology regimen combining the fluoropyrimidine prodrug capecitabine, the platinum chemotherapy oxaliplatin, and the HER2-targeted monoclonal antibody trastuzumab. Capecitabine is converted to 5‑fluorouracil in tumors to inhibit thymidylate synthase and DNA synthesis; oxaliplatin forms DNA crosslinks that block replication and repair; trastuzumab binds HER2 (ERBB2) to inhibit receptor signaling and mediate antibody-dependent cellular cytotoxicity. The combination is used for HER2‑positive gastric or gastro‑oesophageal junction cancers and has been studied as trastuzumab plus XELOX (capecitabine + oxaliplatin) with high response rates in HER2‑positive advanced gastric cancer.[1][4][6]
- Brand names
- HerceptinXelodaEloxatin
- Other names
- trastuzumab + CAPOXtrastuzumab + OCAPtrastuzumab + XELOX
02
Targets
TS (Thymidylate synthase)ERBB2 (Erb-b2 receptor tyrosine kinase 2)DNA
Beyond the preview
Go deeper on capecitabine + oxaliplatin + trastuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on capecitabine + oxaliplatin + trastuzumab.